Consolidated statement of total recognised gains & losses ------------------------- Annual report 2000 - contents ------------------------- Financial summary ------------------------- Joint statement by the Chairman & the CEO ------------------------- Description of business ------------------------- Corporate Governance ------------------------- Remuneration Report ------------------------- Operating & Financial Review & Prospects ------------------------- Directors' statements of responsibility ------------------------- Report by the auditors ------------------------- Consolidated statement of profit & loss ------------------------- Consolidated statement of total recognised gains & losses ------------------------- Consolidated statement of cash flow ------------------------- Consolidated balance sheet ------------------------- Reconciliation of movements in equity shareholders' funds ------------------------- Company balance sheet ------------------------- Notes to financial statements ------------------------- Group companies ------------------------- Principal financial statements in US$ ------------------------- Financial record ------------------------- Shareholder Return ------------------------- Taxation information for shareholders ------------------------- Shareholder information ------------------------- Share capital ------------------------- Cross reference to Form 20-F ------------------------- Glossary of terms ------------------------- Contact details
2000 £m 1999 £m 1998 £m Profit attributable to shareholders 4,154 2,859 2,435 Exchange movements on overseas net assets (23) (272) 4 UK tax on exchange movements 16 (44) 24 Total recognised gains and losses 4,147 2,543 2,463               Updated March 22, 2001 - © 2001-2002 GlaxoSmithKline - All Rights Reserved Legal Notices - Privacy Statement